Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00181636
Status:
COMPLETED
Last Update Posted:
2007-04-24
First Post:
2005-09-12
Brief Title:
Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2007-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine whether the investigational drug galantamine-CR Reminyl- Controlled Release capsule is useful in improving problems with memory in bipolar patients with stable mood This study is being done because a large proportion of patients with bipolar disorder experience significant memory problems even when their mood is stable after adequate treatment These memory problems have been associated with poor daily social functioning Studying galantamine-CR in this population may provide a new clinical way to combat memory problems in stable patients with bipolar disorder
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None